Scinai Immunotherapeutics Reports Q3 2024 Results

Ticker: SCNI · Form: 6-K · Filed: Nov 25, 2024 · CIK: 1611747

Scinai Immunotherapeutics Ltd. 6-K Filing Summary
FieldDetail
CompanyScinai Immunotherapeutics Ltd. (SCNI)
Form Type6-K
Filed DateNov 25, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: financial-results, business-update, foreign-private-issuer

TL;DR

Scinai Immunotherapeutics dropped its Q3 2024 earnings report and business update.

AI Summary

Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on November 25, 2024, to report its Q3 2024 financial results and provide a business update, as announced in a press release on November 22, 2024. The company is incorporated in Israel and its fiscal year ends on December 31.

Why It Matters

This filing provides investors with an update on Scinai Immunotherapeutics' financial performance and business progress during the third quarter of 2024.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing (6-K) and does not contain new material events or significant financial changes.

Key Players & Entities

  • Scinai Immunotherapeutics Ltd. (company) — Filer
  • BiondVax Pharmaceuticals Ltd. (company) — Former company name
  • November 22, 2024 (date) — Date of press release
  • Q3 2024 (period) — Financial reporting period
  • November 25, 2024 (date) — Filing date

FAQ

What type of report is Scinai Immunotherapeutics filing?

Scinai Immunotherapeutics is filing a Form 6-K, which is a Report of Foreign Private Issuer.

When did Scinai Immunotherapeutics announce its Q3 2024 financial results?

The company announced its Q3 2024 financial results and business update in a press release issued on November 22, 2024.

What is the former name of Scinai Immunotherapeutics Ltd.?

The former name of Scinai Immunotherapeutics Ltd. was BiondVax Pharmaceuticals Ltd.

What is the fiscal year end for Scinai Immunotherapeutics Ltd.?

The fiscal year end for Scinai Immunotherapeutics Ltd. is December 31.

What is the filing date of this Form 6-K?

This Form 6-K was filed on November 25, 2024.

Filing Stats: 253 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-11-25 09:20:41

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: November 25, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.